Vaccination with celecoxib-treated dendritic cells improved cellular immune responses in an animal breast cancer model

• Published in: Advances in medical sciences 2023-03, Vol.68 (1), p.157-168
• Main Authors: Zandvakili, Raziyeh, Basirjafar, Pedram, Masoumi, Javad, Zainodini, Nahid, Taghipour, Zahra, Khorramdelazad, Hossein, Yousefi, Soheila, Tavakoli, Tayyebeh, Safdel, Sepehr, Gheitasi, Mahsa, Ayoobi, Fatemeh, Jafarzadeh, Abdollah
• Format: Article
• Language: English
• Subjects: Animals; Breast cancer; Celecoxib; Celecoxib - pharmacology; Celecoxib - therapeutic use; Dendritic cell vaccine; Dendritic Cells; Forkhead Transcription Factors; Granzymes; Immunity, Cellular; Immunotherapy; Interleukin-12; Lipopolysaccharides; Mice; Neoplasms; T cells; Transforming Growth Factor beta; Vaccination; Vaccines
• ISSN: 1896-1126; 1898-4002
• DOI: 10.1016/j.advms.2023.03.002

Prostaglandin E2 (PGE2), a product of cyclooxygenase (COX) pathway of arachidonic acid, exerts inhibitory impacts on dendritic cell (DC) activity to repress anti-tumor immune responses. Therefore, targeting COX during DC vaccine generation may enhance DC-mediated antitumor responses. We aimed to investigate the impacts of DC vaccine treated with celecoxib (CXB), a selective COX2 inhibitor, on some T cell-related parameters. Breast cancer (BC) was induced in BALB/c mice, and then they received DC vaccine treated with lipopolysaccharide (LPS-mDCs), LPS with a 5 ​μM dose of CXB (LPS/CXB5-mDCs) and LPS with a 10 ​μM dose of CXB (LPS/CXB10-mDCs). The frequency of splenic Th1 and Treg cells and amounts of IFN-γ, IL-12 and TGF-β production by splenocytes, as well as, the expression of Granzyme-B, T-bet and FOXP3 in tumors were determined using flow cytometry, ELISA, and real-time PCR, respectively. Compared with untreated tumor group (T-control), treatment with LPS/CXB5-mDCs and LPS/CXB10-mDCs decreased tumor growth (P ​= ​0.009 and P ​